보고서 요약(국문)

개요
전 세계 헤르만스키-푸들락 증후군 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX억 달러에 이를 것으로 예상됩니다.

헤르만스키-푸들락 증후군(HPS)은 어댑터 단백질 3(AP-3) 및 리소좀 관련 소기관 생합성 복합체 1, 2, 3(BLOC-1, BLOC-2, BLOC-3)의 구성 요소를 암호화하는 11개 유전자 중 하나에서 동형접합 또는 복합 이형접합 돌연변이에 의해 발생합니다. 이 네 가지 복합체는 모두 세포 내 리소좀 및 리소좀 관련 소기관(LROS)의 생합성 및 이동을 지원합니다. LROS에는 멜라노솜, 혈소판 치밀체(델타 과립이라고도 함), 제2형 폐포세포의 층상체, 세포독성 및 억제 T 세포, 자연 살해(NK) 세포의 과립 단백질이 포함됩니다.
HPS 환자는 혈소판 응집 장애와 관련된 출혈 경향을 보입니다. 이 증후군 환자의 혈소판은 콜라겐, 트롬빈, 에피네프린, 아데노신 이인산(ADP)에 대해 비정상적인 응집 반응을 나타냅니다.
또한, 헤르만스키 푸들락 증후군 시장은 광범위한 소비자층, 출혈 문제에 대한 인식 증가, 접근 가능한 치료법, 유리한 보상 정책 등 다양한 요인에 의해 성장하고 있으며, Ferring Pharmaceuticals, Dr. Reddy's, Sagent Pharma, Ubi Pharm 등의 주요 기업들이 시장을 주도하고 있습니다.
시장 동향
희귀 질환의 증가
희귀 질환의 증가는 예측 기간 동안 시장 성장을 촉진하는 주요 요인 중 하나입니다. 희귀 질환은 의료 분야 전반에 걸쳐 존재합니다. 낭포성 섬유증처럼 널리 알려진 질환도 있지만, 고양이 눈 증후군처럼 덜 알려진 질환도 있습니다. 대부분의 암(일부 유형을 제외하고)은 희귀 질환입니다. 희귀 신경계 및 신경근육 질환, 대사 질환, 염색체 이상, 피부 질환, 뼈 및 골격 질환, 그리고 심장, 혈액, 폐, 신장 및 기타 신체 장기와 계통에 영향을 미치는 희귀 질환도 있습니다.
예를 들어, 미국 국립보건원(NIH)에 따르면 약 7,000가지의 희귀 질환이 2,500만에서 3,000만 명의 미국인에게 영향을 미치고 있습니다. 이는 미국인 10명 중 1명, 또는 엘리베이터마다 한 명, 버스마다 네 명꼴로 희귀 질환을 앓고 있다는 것을 의미합니다.
헤르만스키 푸들락 증후군(HPS) 유병률 증가
헤르만스키 푸들락 증후군의 유병률 증가는 예측 기간 동안 시장 성장을 촉진하는 주요 요인 중 하나입니다. 예를 들어, NCBI에 발표된 최신 논문에 따르면 헤르만스키-푸들락 증후군(HPS)은 전 세계적으로 인구 100만 명당 1~9명꼴로 발생하는 희귀 질환이지만 특정 인구 집단에서는 더 흔합니다. 예를 들어 푸에르토리코 북서부 지역에서는 인구 1,800명당 1명꼴로 발생하며, 약 22명 중 1명이 돌연변이 보인자입니다. 푸에르토리코의 HPS 1형 환자 대부분은 HPS1 유전자 엑손 15에 있는 동일한 16염기쌍 중복 돌연변이를 가지고 있습니다.
낮은 규제 준수율이 시장 성장을 저해할 것입니다.
개발도상국의 국가 기관 및 기타 단체들이 특정 질환에 대한 인식을 제고하지 못하여 검사 보급률이 낮습니다. 이러한 문제는 조기 진단과 적절한 환자 치료를 방해하여 시장 성장을 저해합니다. HPS 환자는 수술 전 폐 평가를 받아야 합니다. 마취팀은 이 증후군의 일부로서 출혈 경향과 잠재적인 폐 합병증에 대해 인지하고 있어야 합니다. 헤르만스키 푸들락 증후군(HPS) 환자는 전신 마취 후 폐 합병증을 겪을 수 있습니다. 또한, 이 증후군 환자는 수술 후 세심한 모니터링이 필요합니다.
세분화 분석
전 세계 헤르만스키 푸들락 증후군 시장은 유형, 치료 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
치료 유형 부문에서 데스모프레신 부문은 헤르만스키 푸들락 증후군 시장 점유율의 약 41.7%를 차지했습니다.
치료 유형 부문에서 데스모프레신 부문은 41.7%를 차지하며, 향후에도 시장을 주도할 것으로 예상됩니다. HPS에서 데스모프레신 아세테이트의 효과는 개별 환자의 특정 출혈 증상과 혈소판 기능 장애 정도에 따라 달라질 수 있습니다. 경우에 따라 특정 출혈 문제에 대해 어느 정도 완화 효과를 제공할 수 있습니다.
HPS 환자의 과다 출혈은 데스모프레신(DDAVP)과 같이 혈액 응고를 촉진하는 약물로 치료할 수 있으며, 이는 일부 환자에게 효과적인 것으로 나타났습니다. 다른 치료제로는 아미노카프로산, 트라넥사믹산, 재조합 제7응고인자 등이 있습니다. 심각한 출혈의 경우 혈소판 수혈을 사용할 수 있으며, 가능하면 조직 적합 혈소판 수혈이 권장됩니다.
지역별 시장 점유율
북미, 시장 점유율 약 38.4% 차지
북미는 비용 효율성, 의료 시설 접근성, 개선된 치료 옵션, 출혈 질환에 대한 환자 인식, 민간 및 정부 차원의 치료 관련 정책 추진 등으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다. 또한, 검증된 의료 기술에 대한 초기 수용도와 제약 업계 기업들의 빠른 성장세도 북미 지역 시장의 성장을 뒷받침하고 있습니다.
예를 들어, 2023년 4월 바이오제약 회사인 오션 바이오메디컬(Ocean Biomedical, Inc.)은 헤르만스키-푸들락 증후군(HPS)에 대한 효과적인 치료법 개발에 전념하겠다고 발표했습니다. 이 회사는 폐섬유증 치료 후보 물질인 OCF-203을 HPS로 인한 치명적인 폐섬유증 질환 치료제로 개발할 계획이라고 밝혔습니다.
오션의 항섬유증 플랫폼은 특발성 폐섬유증(IPF) 및 헤르만스키-푸들락 증후군과 같은 질환에 대한 중요한 미충족 수요를 해결하는 것을 목표로 하며, 경피증, 알코올성 간질환, 비알코올성 지방간염(NASH), 신부전과 같은 다른 분야로 확장될 가능성도 있습니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Ferring Pharmaceuticals, Dr Reddy's, Sagent Pharma, Ubi Pharm, Amring Pharmaceuticals, Avet Pharmaceuticals, McKesson, Hybio Pharmaceuticals, Midas Pharma, SG Pharma 등이 있습니다.

COVID-19 영향 분석
COVID-19는 전 세계 헤르만스키 푸들락 증후군 시장에 상당한 영향을 미쳤습니다. 이 증후군은 전문적인 의료 서비스와 치료가 필요한 희귀 질환인데, COVID-19로 인해 의료 시스템이 마비되면서 헤르만스키 푸들락 증후군 환자들이 필요한 치료를 받는 데 드는 비용이 감당하기 어려워졌고, 이는 결국 시장 전반에 악영향을 미쳤습니다.

유형별
• HPS1
• AP3B1
• HPS3
• HPS4
• HPS5
• HPS6
• 기타
치료 유형별
• 데스모프레신 아세테이트
• 경구 피임약
• 정상 혈소판 수혈
투여 경로별
• 경구
• 정맥 주사
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 러시아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
 2022년 10월, 페링 제약과 블랙스톤 생명과학은 나도파라젠 피라도나벡에 대한 협력 관계 재편을 발표했습니다. 고등급, BCG 불응성, 비근육침습성 방광암 환자를 위한 후기 임상 연구 단계의 새로운 유전자 치료법.
 2022년 8월, 뉴욕과 오하이오에 생산 시설을 보유한 캘리포니아 소재 인체 및 동물용 의약품 제조업체인 American Regent, Inc.는 HBT Labs, Inc. 인수를 발표했습니다. HBT Labs는 암 및 중추신경계 질환을 포함한 다양한 치료 적응증을 대상으로 하는 제네릭 및 505(b)(2) 의약품 파이프라인을 보유하고 있습니다.
보고서 구매 이유:

• 유형, 치료 유형, 투여 경로, 유통 채널 및 지역별 글로벌 헤르만스키 푸들락 증후군 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위함입니다.

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위함입니다.

• 모든 세그먼트를 포함한 글로벌 헤르만스키 푸들락 증후군 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 헤르만스키 푸들락 증후군 시장 보고서는 약 61개의 표, 58개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Hermansky Pudlak Syndrome Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
Hermansky-Pudlak syndrome (HPS) is caused by homozygous or compound heterozygous mutations in 1 of 11 genes that encode components in one of four protein complexes: adapter protein 3 (AP-3) and biogenesis of lysosome-related organelles complex 1, 2, and 3 (BLOC-1, BLOC-2, and BLOC-3). All four complexes support intracellular biogenesis and trafficking of lysosome and lysosome-related organelles (LROS). LROS include melanosomes, platelet dense bodies (also called delta granules), lamellar bodies of type II pneumocytes, and granule proteins of cytotoxic and suppressor T cells and natural killer (NK) cells.
Patients with HPS have a bleeding tendency associated with poor platelet aggregation. Platelets in patients with the syndrome have abnormal aggregation with collagen, thrombin, epinephrine, and adenosine diphosphate (ADP).
Furthermore, the Hermansky pudlak syndrome market is driven by various factors the vast consumer base increased awareness of bleeding problems and accessible remedies, and advantageous compensation policies drive the industry have significant key players like Ferring Pharmaceuticals, Dr. Reddy's, Sagent Pharma, Ubi Pharm and others.
Dynamics
Increasing Prevalence of Rare Diseases
The rise in the prevalence of rare diseases is one of the key factors that help the market during the forecast period. Rare diseases are present across the medical spectrum. Some are widely recognized by name, such as cystic fibrosis, while others are less known, such as cat eye syndrome. Most cancers (all but a few types) are rare. There are rare neurological and neuromuscular diseases, metabolic diseases, chromosomal disorders, skin diseases, bone and skeletal disorders, and rare diseases affecting the heart, blood, lungs, kidneys, and other body organs and systems.
For instance, according to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans. This equates to 1 in 10 Americans, or one on every elevator and four on every bus.
Rise in the Prevalence of Hermansky Pudlak Syndrome(HPS)
The rise in the prevalence of Hermansky Pudlak syndrome is one of the key factors that help the market to grow during the forecast period. For instance, according to an updated article published at NCBI Hermansky-Pudlak syndrome (HPS) is rare, with a prevalence of 1 to 9 in 1,000,000 individuals worldwide but is more common in certain populations. As an example, the prevalence is 1 in 1800 individuals in the northwestern region of Puerto Rico, where approximately 1 in 22 individuals are carriers of the mutation. Most HPS type 1-affected individuals in Puerto Rico have the same founder 16-base-pair duplication in exon 15 of HPS1.
Low Regulatory Compliance Will Stifle Market Growth
The failure of national organizations and other institutions in poor countries to raise awareness about certain ailments resulted in low testing penetration. This issue stifles market growth by hindering early diagnosis and appropriate patient care. Patients with HPS should obtain a preoperative pulmonary evaluation. The anesthesia team should be aware of bleeding tendencies and potential pulmonary complications as part of the syndrome. Patients with HPS may have pulmonary complications following general anaesthesia. Further, patients with the syndrome need careful post-operative monitoring.
Segment Analysis
The global Hermansky Pudlak Syndrome market is segmented based on type, therapy type, route of administration, distribution channel and region.
The Desmopressin Segment From the Therapy Type Segment Accounted For Approximately 41.7% of Hermansky Pudlak Syndrome Share
The desmopressin segment from the therapy type segment accounted for 41.7% and it is expected to be dominated during the The effectiveness of desmopressin acetate in HPS would likely depend on the individual's specific bleeding symptoms and the extent of platelet dysfunction. In some cases, it might provide modest relief for certain bleeding issues.
Excessive bleeding in individuals with HPS may be treated with medications that promote blood coagulation such as desmopressin (DDAVP), which has been shown to be effective for some patients. Other agents include aminocaproic acid, tranexamic acid and recombinant factor seven. For more serious bleeding, platelet transfusions can also be used and if possible, tissue-matched platelets are recommended.
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share
North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, due to its cost-effectiveness and access to healthcare facilities, improved treatment options, Patient awareness of bleeding disorders, as well as private-sector and government Therapeutics initiatives, assisting in market development. Also due to the preliminary stage acceptance of proven medical technology, the market in the area is the rapid ongoing expansion of firms operating in the drug sector.
For instance, in April 2023, Biopharma company Ocean Biomedical, Inc. announced its commitment to developing viable treatment options for Hermansky-Pudlak Syndrome (HPS). The company disclosed its plans to target OCF-203, its pulmonary fibrosis treatment candidate, as a therapeutic for fatal pulmonary fibrotic conditions caused by HPS.
Ocean’s anti-fibrosis platform aims to target significant unmet needs for conditions like Idiopathic Pulmonary Fibrosis (IPF) and Hermansky-Pudlak Syndrome, and it has the potential to expand further into other areas like scleroderma, alcoholic liver disease, NASH, and kidney failure.
Competitive Landscape
The major global players in the market include Ferring Pharmaceuticals, Dr Reddy's, Sagent Pharma, Ubi Pharm, Amring Pharmaceuticals, Avet Pharmaceuticals, McKesson, Hybio Pharmaceuticals, Midas Pharma, SG Pharma and among others.
COVID-19 Impact Analysis
The overall impact of COVID-19 had a substantial impact on the global Hermansky Pudlak syndrome market, as this syndrome is a rare disease that requires specialized medical care and treatment options but covid 19 has disrupted the overall healthcare systems in which people having Hermansky Pudlak syndrome treatment options became unaffordable which indeed impacted the overall market.
By Type
• HPS1
• AP3B1
• HPS3
• HPS4
• HPS5
• HPS6
• Others
By Therapy Type
• Desmopressin Acetate
• Oral Contraceptives
• Transfusions of Normal Blood Platelets
By Route of Administration
• Oral
• Intravenous
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Russia
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
 In October 2022, Ferring Pharmaceuticals and Blackstone Life Sciences announced a restructured cooperation in nadofaragene firadonavec, an experimental new gene therapy in late-stage research for patients with high-grade, Bacillus Calmette-Guerin refractory, non-muscle invasive bladder cancer.
 In August 2022, American Regent, Inc., a California-based maker of medicines for human and veterinary use with production facilities in New York and Ohio, announced the acquisition of HBT Labs, Inc. HBT Labs offers a pipeline of generic and 505(b)(2) pharmaceutical medicines that target a variety of therapeutic indications, including cancer and CNS diseases.
Why Purchase the Report?
• To visualize the global Hermansky Pudlak Syndrome market segmentation based on type, therapy type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global Hermansky Pudlak Syndrome market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The Global Hermansky Pudlak Syndrome Market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Therapy Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Rare Diseases
4.1.1.2. Rise in the prevalence of Hermansky Pudlak Syndrome(HPS)
4.1.2. Restraints
4.1.2.1. Low Regulatory Compliance Will Stifle Market Growth
4.1.3. Opportunity
4.1.3.1. Long-Term Treatment Approach
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. HPS1 *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. AP3B1
7.4. HPS3
7.5. HPS4
7.6. HPS5
7.7. HPS6
7.8. Others
8. By Therapy Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.1.2. Market Attractiveness Index, By Therapy Type
8.2. Desmopressin Acetate *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oral Contraceptives
8.4. Transfusions of Normal Blood Platelets
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Ferring Pharmaceuticals *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Dr. Reddy's
13.3. Sagent Pharma
13.4. UbiPharm
13.5. Amring Pharmaceuticals
13.6. Avet Pharmaceuticals
13.7. McKesson
13.8. Hybio Pharmaceuticals
13.9. Midas Pharma
13.10. SG Pharma
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Ferring Pharmaceuticals, 4.	Key Developments, Dr. Reddy's, Sagent Pharma, UbiPharm, Amring Pharmaceuticals, Avet Pharmaceuticals, McKesson, Hybio Pharmaceuticals, Midas Pharma, SG Pharma

표 목록 (Tables)

List of Tables

Table 1 Global Hermansky Pudlak Syndrome Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Hermansky Pudlak Syndrome Market Value, By Therapy Type, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Hermansky Pudlak Syndrome Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Hermansky Pudlak Syndrome Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Hermansky Pudlak Syndrome Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Hermansky Pudlak Syndrome Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Hermansky Pudlak Syndrome Market Value, By Type, 2021-2030 (US$ Billion)

Table 8 Global Hermansky Pudlak Syndrome Market Value, By Therapy Type, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Hermansky Pudlak Syndrome Market Value, By Therapy Type, 2021-2030 (US$ Billion)

Table 10 Global Hermansky Pudlak Syndrome Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Hermansky Pudlak Syndrome Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 12 Global Hermansky Pudlak Syndrome Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Hermansky Pudlak Syndrome Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 14 Global Hermansky Pudlak Syndrome Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Hermansky Pudlak Syndrome Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Hermansky Pudlak Syndrome Market Value, By Type, 2021-2030 (US$ Billion)

Table 17 North America Hermansky Pudlak Syndrome Market Value, By Therapy Type, 2021-2030 (US$ Billion)

Table 18 North America Hermansky Pudlak Syndrome Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 19 North America Hermansky Pudlak Syndrome Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 North America Hermansky Pudlak Syndrome Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Hermansky Pudlak Syndrome Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 South America Hermansky Pudlak Syndrome Market Value, By Therapy Type, 2021-2030 (US$ Billion)

Table 23 South America Hermansky Pudlak Syndrome Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 24 South America Hermansky Pudlak Syndrome Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 25 South America Hermansky Pudlak Syndrome Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Hermansky Pudlak Syndrome Market Value, By Type, 2021-2030 (US$ Billion)

Table 27 Europe Hermansky Pudlak Syndrome Market Value, By Therapy Type, 2021-2030 (US$ Billion)

Table 28 Europe Hermansky Pudlak Syndrome Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 29 Europe Hermansky Pudlak Syndrome Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 30 Europe Hermansky Pudlak Syndrome Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Hermansky Pudlak Syndrome Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Hermansky Pudlak Syndrome Market Value, By Therapy Type, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Hermansky Pudlak Syndrome Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Hermansky Pudlak Syndrome Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Hermansky Pudlak Syndrome Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Hermansky Pudlak Syndrome Market Value, By Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Hermansky Pudlak Syndrome Market Value, By Therapy Type, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Hermansky Pudlak Syndrome Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Hermansky Pudlak Syndrome Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 40 Ferring Pharmaceuticals: Overview

Table 41 Ferring Pharmaceuticals: Product Portfolio

Table 42 Ferring Pharmaceuticals: Key Developments

Table 43 Dr. Reddy's: Overview

Table 44 Dr. Reddy's: Product Portfolio

Table 45 Dr. Reddy's: Key Developments

Table 46 Sagent Pharma: Overview

Table 47 Sagent Pharma: Product Portfolio

Table 48 Sagent Pharma: Key Developments

Table 49 UbiPharm: Overview

Table 50 UbiPharm: Product Portfolio

Table 51 UbiPharm: Key Developments

Table 52 Amring Pharmaceuticals: Overview

Table 53 Amring Pharmaceuticals: Product Portfolio

Table 54 Amring Pharmaceuticals: Key Developments

Table 55 Avet Pharmaceuticals: Overview

Table 56 Avet Pharmaceuticals: Product Portfolio

Table 57 Avet Pharmaceuticals: Key Developments

Table 58 McKesson: Overview

Table 59 McKesson: Product Portfolio

Table 60 McKesson: Key Developments

Table 61 Hybio Pharmaceuticals: Overview

Table 62 Hybio Pharmaceuticals: Product Portfolio

Table 63 Hybio Pharmaceuticals: Key Developments

Table 64 Midas Pharma: Overview

Table 65 Midas Pharma: Product Portfolio

Table 66 Midas Pharma: Key Developments

Table 67 SG Pharma: Overview

Table 68 SG Pharma: Product Portfolio

Table 69 SG Pharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Hermansky Pudlak Syndrome Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Hermansky Pudlak Syndrome Market Share, By Therapy Type, 2022 & 2030 (%)

Figure 4 Global Hermansky Pudlak Syndrome Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Hermansky Pudlak Syndrome Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Hermansky Pudlak Syndrome Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Hermansky Pudlak Syndrome Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 HPS1 Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 9 AP3B1 Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 10 HPS3 Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 11 HPS4 Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 12 HPS5 Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 13 HPS6 Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 14 Others Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 15 Global Hermansky Pudlak Syndrome Market Y-o-Y Growth, By Therapy Type, 2022-2030 (%)

Figure 16 Desmopressin Acetate Therapy Type in Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 17 Oral Contraceptives Therapy Type in Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 18 Transfusions of Normal Blood Platelets Therapy Type in Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 19 Global Hermansky Pudlak Syndrome Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 20 Oral Route of Administration in Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 21 Intravenous Route of Administration in Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 22 Global Hermansky Pudlak Syndrome Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 23 Hospital Pharmacies Distribution Channel in Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 24 Retail Pharmacies Distribution Channel in Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 25 Online Pharmacies Distribution Channel in Global Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 26 Global Hermansky Pudlak Syndrome Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 27 North America Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 28 Asia-Pacific Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 29 Europe Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 30 South America Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 31 Middle East and Africa Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 32 North America Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 33 North America Hermansky Pudlak Syndrome Market Share, By Type, 2022 & 2030 (%)

Figure 34 North America Hermansky Pudlak Syndrome Market Share, By Therapy Type, 2022 & 2030 (%)

Figure 35 North America Hermansky Pudlak Syndrome Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 36 North America Hermansky Pudlak Syndrome Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 North America Hermansky Pudlak Syndrome Market Share, By Country, 2022 & 2030 (%)

Figure 38 South America Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 39 South America Hermansky Pudlak Syndrome Market Share, By Type, 2022 & 2030 (%)

Figure 40 South America Hermansky Pudlak Syndrome Market Share, By Therapy Type, 2022 & 2030 (%)

Figure 41 South America Hermansky Pudlak Syndrome Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 42 South America Hermansky Pudlak Syndrome Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 43 South America Hermansky Pudlak Syndrome Market Share, By Country, 2022 & 2030 (%)

Figure 44 Europe Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 45 Europe Hermansky Pudlak Syndrome Market Share, By Type, 2022 & 2030 (%)

Figure 46 Europe Hermansky Pudlak Syndrome Market Share, By Therapy Type, 2022 & 2030 (%)

Figure 47 Europe Hermansky Pudlak Syndrome Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 Europe Hermansky Pudlak Syndrome Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 49 Europe Hermansky Pudlak Syndrome Market Share, By Country, 2022 & 2030 (%)

Figure 50 Asia-Pacific Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 51 Asia-Pacific Hermansky Pudlak Syndrome Market Share, By Type, 2022 & 2030 (%)

Figure 52 Asia-Pacific Hermansky Pudlak Syndrome Market Share, By Therapy Type, 2022 & 2030 (%)

Figure 53 Asia-Pacific Hermansky Pudlak Syndrome Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 54 Asia-Pacific Hermansky Pudlak Syndrome Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 55 Asia-Pacific Hermansky Pudlak Syndrome Market Share, By Country, 2022 & 2030 (%)

Figure 56 Middle East & Africa Hermansky Pudlak Syndrome Market Value, 2021-2030 (US$ Billion)

Figure 57 Middle East & Africa Hermansky Pudlak Syndrome Market Share, By Type, 2022 & 2030 (%)

Figure 58 Middle East & Africa Hermansky Pudlak Syndrome Market Share, By Therapy Type, 2022 & 2030 (%)

Figure 59 Middle East & Africa Hermansky Pudlak Syndrome Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 60 Middle East & Africa Hermansky Pudlak Syndrome Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 61 Ferring Pharmaceuticals: Financials

Figure 62 Dr. Reddy's: Financials

Figure 63 Sagent Pharma: Financials

Figure 64 UbiPharm: Financials

Figure 65 Amring Pharmaceuticals: Financials

Figure 66 Avet Pharmaceuticals: Financials

Figure 67 McKesson: Financials

Figure 68 Hybio Pharmaceuticals: Financials

Figure 69 Midas Pharma: Financials

Figure 70 SG Pharma: Financials

글로벌 헤르만스키 푸들락 증후군 시장 – 2023-2030

Global Hermansky Pudlak Syndrome Market - 2023-2030